64cu-llp2a

64cu-llp2a is a radiopharmaceutical diagnostic agent composed of the radioactive isotope copper-64 chelated to LLP2A, a high-affinity peptidomimetic ligand targeting very late antigen–4 (VLA4; also known as integrin α4β1). VLA4 is overexpressed in malignant multiple myeloma cells and in the inflammatory microenvironment associated with hematologic malignancies. The drug is used for positron emission tomography (PET) imaging to detect and monitor multiple myeloma and other hematologic cancers. It enables molecular imaging of disease lesions by binding specifically to VLA4-expressing cells, allowing for improved detection and disease management. Developed primarily at Washington University School of Medicine, it has shown favorable safety and dosimetry profiles in early human studies[3][5][6].

Other names

[64Cu]Cu-CB-TE1A1P-LLP2Acopper Cu 64-CB-TE1A1P-PEG4-LLP2A